Date: 2012-02-01
Type of information: Development agreement
Compound: undisclosed
Company: Octoplus (The Netherlands) Ferring Pharmaceuticals (Switzerland)
Therapeutic area: undisclosed
Type agreement: development
manufacturing
production
Action mechanism:
Disease: undisclosed
Details: OctoPlus has concluded a formulation development and manufacturing contract with Ferring Pharmaceuticals. The undisclosed contract value will make a material contribution to OctoPlus' 2012 revenues. Further details on the compound and activities are not disclosed.
Financial terms:
Latest news:
